Comparative Pharmacology
Head-to-head clinical analysis: ALLERFED versus DRYTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLERFED versus DRYTEC.
ALLERFED vs DRYTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALLERFED is a combination of an antihistamine (fexofenadine) and a decongestant (pseudoephedrine). Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine effects, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor activation, causing vasoconstriction of nasal mucosa.
Drytec is an antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic symptoms.
1 tablet (pseudoephedrine 60 mg / triprolidine 2.5 mg) orally every 4-6 hours; not to exceed 4 doses per 24 hours.
1-2 tablets (paracetamol 500 mg/pseudoephedrine 30 mg) orally every 4-6 hours; maximum 8 tablets per day.
None Documented
None Documented
Terminal elimination half-life 20-24 hours; clinically significant for once-daily dosing in seasonal allergic rhinitis.
Terminal elimination half-life is approximately 3.5 to 4 hours in adults with normal renal function; may be prolonged in elderly or patients with renal impairment.
Primarily renal (approximately 60-70% as unchanged drug and metabolites); minor biliary (10-15%); fecal (5-10%).
Renal excretion of unchanged drug accounts for approximately 65% of the administered dose; fecal/biliary elimination contributes about 35%.
Category C
Category C
Decongestant
Decongestant